Drug Candidates

6 candidates mapped to SDH-deficient disease pathways

All (15)established (4)clinical trial (2)preclinical (6)theoretical (3)
Everolimus

Afinitor

preclinical

mTOR inhibitor (rapalog)

Mtor Pi3k Akt
Evidence Score
55
FDA Approved
Azacitidine

Vidaza

preclinical

DNA methyltransferase inhibitor (hypomethylating agent)

Epigenetic Dysregulation
Evidence Score
52
FDA Approved
Decitabine

Dacogen

preclinical

DNA methyltransferase inhibitor (hypomethylating agent)

Epigenetic Dysregulation
Evidence Score
50
FDA Approved
Metformin

Glucophage

preclinical

Biguanide / Complex I inhibitor / AMPK activator

Mtor Pi3k AktOxidative Stress Ros
Evidence Score
40
FDA Approved
Ascorbic Acid (High-dose IV)
preclinical

TET enzyme cofactor / α-KG-dependent dioxygenase activator

Epigenetic DysregulationOxidative Stress Ros
Evidence Score
38
Dichloroacetate (DCA)
preclinical

Pyruvate dehydrogenase kinase inhibitor

Hif PseudohypoxiaOxidative Stress Ros
Evidence Score
35